GYRE THERAPEUTICS, INC. 8-K

What Happened
Gyre Therapeutics, Inc. announced on June 1, 2026 that it made an updated corporate presentation available on its website and furnished that presentation as Exhibit 99.1 in a Form 8-K filed June 2, 2026 under Item 7.01 (Regulation FD Disclosure). The presentation is dated June 2026 and the 8-K notes the exhibit is incorporated by reference.

Key Details

• Updated corporate presentation posted on the company website on June 1, 2026.
• Form 8-K filed June 2, 2026 to satisfy Regulation FD disclosure requirements (Item 7.01).
• The presentation is furnished as Exhibit 99.1 to the 8-K (document dated June 2026).
• The filing does not report earnings, revenue figures, management changes, mergers, or other financial results.

Why It Matters
This filing informs investors that Gyre has publicly released updated corporate information (strategy, pipeline or other investor materials may be included in the deck). Because the disclosure was made under Regulation FD, the material was provided to all investors simultaneously via the company website and the SEC filing. Investors should review the attached Exhibit 99.1 for any material updates; the 8-K itself does not present new financial results, executive changes, or transaction announcements.